Open Access<p>Pharmacokinetic/Pharmacodynamic Interaction Between Evogliptin and Pioglitazone in Healthy Male Subjects</p>
Author(s) -
Inyoung Hwang,
Yun Kim,
Hyounggyoon Yoo,
In Jin Jang,
KyungSang Yu,
Seung Hwan Lee
Publication year - 2020
Publication title -
drug design, development and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.964
H-Index - 64
ISSN - 1177-8881
DOI - 10.2147/dddt.s275336
Subject(s) - pioglitazone , pharmacokinetics , cmax , pharmacodynamics , medicine , pharmacology , crossover study , type 2 diabetes , endocrinology , diabetes mellitus , placebo , alternative medicine , pathology
Evogliptin is a newly developed oral glucose-lowering medication of the dipeptidyl peptidase 4 (DPP-4) inhibitor class for type 2 diabetes mellitus. The combination of a DPP-4 inhibitor with pioglitazone is a promising therapeutic option. The aim of the present study was to evaluate the pharmacokinetic and pharmacodynamic interaction between evogliptin and pioglitazone.